trial · primary record
Zanzalintinib
Phase 2
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2030-11-01 |
| Primary endpoint | Safety and adverse events (AEs) |
| Registry ID | NCT07283731 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:04.009Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07283731
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Zanzalintinib · compound